Dr Snape wrote to the haemophilia centre directors to inform them that "limited supplies" of a heated Factor 8 concentrate would be available in early February and that would be "the product generally available for the next three to four months, the amounts being 50-60% of what would otherwise have been supplied as unheated concentrate." Read more about Dr Snape wrote to the haemophilia centre directors to inform them that "limited supplies" of a heated Factor 8 concentrate would be available in early February and that would be "the product generally available for the next three to four months, the amounts being 50-60% of what would otherwise have been supplied as unheated concentrate."
Cutter and Alpha both published the results of tests which showed that their heating processes had inactivated HTLV-3/HIV virus load to a degree sufficient to show they were almost certainly (generally) safe, and the use of heat-treated product had been strongly endorsed by "The Lancet". Read more about Cutter and Alpha both published the results of tests which showed that their heating processes had inactivated HTLV-3/HIV virus load to a degree sufficient to show they were almost certainly (generally) safe, and the use of heat-treated product had been strongly endorsed by "The Lancet".
In an editorial "The Lancet" said that the time had come when it was now reasonable to switch to heat-treated products. Read more about In an editorial "The Lancet" said that the time had come when it was now reasonable to switch to heat-treated products.
Dr Smith told Dr Lane: "Anything going into PFL's oven on 11th December will not be issuable until January", and asked if there should be an interim policy on the issue of "what little dry-heated 8CRV we already stock?" Read more about Dr Smith told Dr Lane: "Anything going into PFL's oven on 11th December will not be issuable until January", and asked if there should be an interim policy on the issue of "what little dry-heated 8CRV we already stock?"
Dr Smith told Dr Lane: "US companies say they can provide UK with more than enough heated product, today." Read more about Dr Smith told Dr Lane: "US companies say they can provide UK with more than enough heated product, today."
Dr Lane's team gave him a "very provisional" date of 1 April 1985 for the implementation of heat treatment, and said it was "impossible to judge its feasibility." Read more about Dr Lane's team gave him a "very provisional" date of 1 April 1985 for the implementation of heat treatment, and said it was "impossible to judge its feasibility."
Dr Lane reported promising trials of a heat-treated product to the CBLA Central Committee for Research and Development in Blood Transfusion and that the time scale for the new product he had in mind ("8Y") was a year. Read more about Dr Lane reported promising trials of a heat-treated product to the CBLA Central Committee for Research and Development in Blood Transfusion and that the time scale for the new product he had in mind ("8Y") was a year.
Dr Harris asked Dr Lane to refer his plan to an advisory group to consider if the evidence for inactivation of HTLV-3 by heat was "sufficient to warrant" taking such a step, "particularly if a screening test can be made available." Read more about Dr Harris asked Dr Lane to refer his plan to an advisory group to consider if the evidence for inactivation of HTLV-3 by heat was "sufficient to warrant" taking such a step, "particularly if a screening test can be made available."
Dr Lane wrote to Dr Edmund Harris at the DHSS to notify him of his plan to dry heat all the Factor 8 to be produced "on the empirical basis that it has a satisfactory process efficacy for inactivation of HTLV-III." Read more about Dr Lane wrote to Dr Edmund Harris at the DHSS to notify him of his plan to dry heat all the Factor 8 to be produced "on the empirical basis that it has a satisfactory process efficacy for inactivation of HTLV-III."
"The Lancet" published an article which in its summary said that the findings reported in it "support the possible role of retroviruses in AIDS, and indicate that factor VIII concentrates must be heated to inactivate these infectious viruses." Read more about "The Lancet" published an article which in its summary said that the findings reported in it "support the possible role of retroviruses in AIDS, and indicate that factor VIII concentrates must be heated to inactivate these infectious viruses."